Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors

Seminars in Oncology

Volumn 36, Issue 1, 2009, Pages 65-74

  Greco, F Anthony ^a   Pavlidis, Nicholas ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; SEMUSTINE; TOPOTECAN; VINCRISTINE;

ARTICLE; BLEEDING; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARCINOMA; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON PERFORATION; COLORECTAL CANCER; DRUG FATALITY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

HUMANS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58549096556     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.10.005     Document Type: Article

References (60)

1. Greco F.A., and Hainsworth J.D. Cancer of unknown primary site. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice oncology. 8th ed. (2008), Lippincott, Philadelphia 2363-2387
2. Muir C. Cancer of unknown primary site. Cancer 75 (1995) 353-356
3. Tracey F.A., Glass P., Roder D., et al. Unknown primary cancer in New South Wales, Sydney Cancer Institute (2008), New South Wales Central Cancer Registry, New South Wales
4. Altman E., and Cadman E. An analysis of 1,539 patients with cancer of unknown primary site. Cancer 57 (1986) 120-124
5. Van de Wouw A.J., Janssen-Heijnen M.L.C., Coebergh J.W.W., et al. Epidemiology of unknown primary tumors; incidence and population-based survival of 1285 patients in Southeast Netherlands 1984-1992. Eur J Cancer 38 (2002) 409-413
6. Hess K.R., Abbruzzese M.C., Lenzi R., et al. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5 (1999) 3403-3410
7. Holmes F.F., and Fouts T.L. Metastatic cancer of unknown primary site. Cancer 26 (1970) 816-820
8. Levi F., Te V.C., Erler G., et al. Epidemiology of unknown primary tumors. Eur J Cancer 38 (2002) 1810-1812
9. Krementz E.T., Cerise E.J., Foster D.C., et al. Metastases of undetermined source. Curr Probl Cancer 4 (1979) 4-37
10. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at the Johns Hopkins Hospital from 1965-1979. Med Pediatr Oncol 10 (1982) 569-574
11. Moertel C.G., Reitmeier R.J., Schutt A.J., et al. Treatment of the patient with adenocarcinoma of unknown primary site. Cancer 30 (1972) 1469-1472
12. Pavlidis N., Briasoulis E., Hainsworth J., and Greco F.A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39 (2003) 1990
13. Casciato D.A. Metastasis of unknown origin. In: Haskell C. (Ed). Cancer treatment. 4th ed. (1995), Saunders, Philadelphia 1128-1148
14. Greco F.A., and Culine S. Chemotherapy for patients with metastatic carcinoma of unknown primary site. In: Fizazi K. (Ed). Carcinoma of an unknown primary site (2006), Taylor & Francis, New York 93-103
15. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 47 (2007) 592-601
16. Hainsworth J.D., Johnson D.H., and Greco F.A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience at a single institution. J Clin Oncol 10 (1992) 912
17. Raber M.N., Faintuch J., and Abbruzzese J. Continuous infusion 5-fluorouracil, etoposide and cis-diamminechloroplatinum in patients with metastatic carcinoma of unknown primary site. Ann Oncol 2 (1991) 519
18. Pavlidis N., Kosmidis P., Skaros D., et al. Subsets of tumors responsive to cisplatin or combinations in patients with carcinoma of unknown primary site. Ann Oncol 3 (1992) 631
19. Van der Gaast A., Verweij J., Henzen-Logmans S.C., et al. Carcinoma of unknown primary: identification of a treatable subset. Ann Oncol 1 (1990) 119
20. Fizazi K., and Schmoll H.J. Randomized trials in patients with carcinoma of an unknown primary: the past, the present, and the future. In: Fizazi K. (Ed). Carcinoma of an unknown primary site (2006), Taylor & Francis, New York 105-114
21. Hainsworth J.D., Erland J.B., Kalman C.A., et al. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 15 (1997) 2385-2395
22. Greco F.A., Erland J.B., Morrissey L.H., et al. Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11 (2000) 211-215
23. Greco F.A., Burris H.A., Litchy S., et al. Gemcitabine, carboplatin, and paclitaxel for patients with unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20 (2002) 1651-1656
24. Greco F.A., Rodriguez G.I., Shaffer D.W., et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 9 (2004) 644-652
25. Hainsworth J.D., Spigel D.R., Farley C., et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: Minnie Pearl Cancer Research Network. J Clin Oncol 25 (2007) 1747-1752
26. Hainsworth J.D., Burris III H.A., Calvert S.W., Willcutt N.T., Scullin Jr. D.C., Bramham J., et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 19 (2001) 335-339
27. Hainsworth J.D., Spigel D.R., Raefsky E.L., Kuzur M.E., Yost K., Kommor M., et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network phase II trial. Cancer 104 (2005) 1992-1997
28. Poussel D., Culine S., Becht C., Romieu G., et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 23 (2003) (3C)
29. Culine S., Ychou M., Fabbro M., Romieu G., and Cupissol D. 5-Fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res 21 (2001) 1455-1457
30. Greco F.A. Paclitaxel/carboplatin plus bevacizumab/erlotinib as first-line treatment for patients with carcinoma of unknown primary site [abstract]. J Clin Oncol 26 (2008) 4607
31. Seve P., Ray-Coquard I., Trillet-Lenoir V., et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinoma of unknown primary site. Cancer 107 (2006) 2698-2702
32. Culine S., Kramar A., Saghatchian M., et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20 (2002) 4679-4683
33. van de Wouw A.J., Jansen R.L., Griffioen A.W., et al. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 24 (2004) 297-301
34. Briasoulis E., Kalofonos H., Bafaloukos D., et al. Carboplatin plus paclitaxel in unknown primary cancer: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 18 (2000) 3101-3107
35. Dowell J.E., Garrett A.M., Shyr Y., et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 91 (2001) 592-597
36. Pittman K.B., Oliver I.N., Koczwara R., et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education collaborative study. Br J Cancer 95 (2006) 1309-1313
37. Culine S., Lortholary A., Voigt J.J., et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study trial for the French Study Group on Carcinomas of Unknown Primary. J Clin Oncol 21 (2003) 3479-3482
38. Balana C., Manzano J.L., Moreno L., et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavorable group of patients with carcinoma of unknown primary site. Ann Oncol 14 (2003) 1425-1429
39. Piga A., Nortilli R., Cetto G.L., et al. Carboplatin, doxorubicin and etoposide in the treatment of tumors of unknown primary site. Br J Cancer 90 (2004) 1898-1904
40. Park Y.H., Ryoo B.Y., Choi S.J., et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavorable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 34 (2004) 681-685
41. Pouessel D., Culine S., Becht C., et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 100 (2004) 1257-1261
42. Briasoulis E., Fountzilus G., Bamias A., et al. Multicenter phase II trial of irinotecan plus oxaliplatin (IROX regimen) in patients with poor-prognosis cancer of unknown primary: a Hellenic Cooperative Group study. Cancer Chemother Pharmacol 62 (2008) 277-284
43. El-Rayes B.F., Shields A.F., Zalupski M., et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary site. Am J Clin Oncol 28 (2005) 152-156
44. Palmeri S., Lorusso V., Palmeri L., et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer 1007 (2006) 2898-2905
45. Schneider B.J., El-Reyes B., Muler J.H., et al. Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site cancer. Cancer 110 (2007) 770-775
46. Berry W., Elkordy M., O'Rourke M., et al. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?. Cancer Invest 25 (2007) 27-31
47. Varadhachary G., Talantov D., Raber M., et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26 (2008) 4442-4448
48. Pentheroudakis G., Golfinopoulos V., and Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43 (2007) 2026-2036
49. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
50. Sandler A.B., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer. N Engl J Med 355 (2006) 2542-2550
51. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
52. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of Fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
53. Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26 (2008) 1443-1451
54. Bunn Jr. P.A. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol 20 (2002) 3565-3567
55. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2000) 91-98
56. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
57. Paccagnella A., Oniga F., Bearz A., et al. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. J Clin Oncol 24 (2006) 681-687
58. Van Cutsem E., Verslype C., and Grusenmeyer P.A. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 25 (2007) 1949-1952
59. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006) 3946-3952
60. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 20 (2002) 3270-3275